DIA426.97-1.07 -0.25%
SPX5,940.46-23.14 -0.39%
IXIC19,142.71-72.75 -0.38%

HP And Tecan Expand Strategic Collaboration To Unveil New Dual Use Single Cell And Reagent Dispenser For Life Science And Pharma Research

Benzinga·05/20/2025 13:31:42
Listen to the news

https://www.hp.com/us-en/newsroom/blogs/2025/HP-Tecan-Expand-Collaboration.html

HP is teaming up with Tecan, a global leader in laboratory automation for life sciences and diagnostics, to launch the Duo Digital DispenserTM, a new solution designed to simplify how researchers isolate individual cells and develop new therapeutics. Powered by HP's inkjet technology, Duo combines the capabilities of the D300e Digital Dispenser and the Uno Single Cell DispenserTM, delivering a major advancement in speed and precision for cancer research and other critical applications in life sciences.
 
By combining single-cell and reagent dispensing into one system, the new instrument significantly improves lab efficiency, reducing sample processing time, increasing reproducibility, and cutting down on labware waste and reagent use. Duo is 40 times faster than conventional methods1 for drug discovery, reducing dosing time from 10 minutes to 15 seconds. Cell dispensing with Duo enables researchers to isolate single cells in less than 5 minutes compared to 1 hour when using traditional cell isolation technology2. The instrument features a single-use disposable component that simplifies setup, minimizes contamination risk, and enables experimental reproducibility.
 
In addition to dispensing cells, Duo enables researchers to dispense reagents without the use of surfactants. This innovation is especially important for scientists developing advanced biologic therapeutics, which can be particularly sensitive to surfactants.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.